Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Generate Biomedicines, Inc.NASDAQ: GENB
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development of $54.56M in Q1 FY2026
Q1 FY2026 research & development was $54.56M.
Context
- Research & development amounted to 704.5% of revenue in FY2025, down 152.4 pp from a year earlier.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 224.7M USD
- Year-over-year change
- +28.2%
- 1-year CAGR
- +28.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 224.7M | +28.2% |
| FY2024 | 2024-12-31 | 175.31M | — |
Research & Development vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 research & development of $224.7M is the highest of the 5 companies compared; the peer median is $126.11M.
- Its year-over-year change of +28.2% is the highest of 5, against a peer median of -18.4%.
- Research & development amounts to 704.5% of revenue for GENB, versus a peer median of 2433.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
GENBGenerate Biomedicines, Inc. | FY2025 | $224.7M | +28.2% | — | 704.5% |
| LTM Sep 2026 | $186.28M | +1.9% | +20.1% | 274.5% | |
| LTM Mar 2026 | $151.37M | -38.7% | +6.7% | 152.0% | |
| LTM Mar 2026 | $100.84M | -42.7% | +0.9% | 7756.8% | |
| LTM Mar 2026 | $84.33M | +24.0% | +11.4% | 4593.1% | |
| Peer median (excluding GENB) | $126.11M | -18.4% | +9.0% | 2433.8% | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 20.46M | 31.89M |
| Gross Margin | 100.0% | 100.0% |
| Research & Development | 175.31M | 224.7M |
| Selling, General & Admin | 42.09M | 42.26M |
| Operating Expenses | 217.4M | 266.96M |
| Depreciation & Amortization | 15.35M | 13.18M |
| EBITDA | (163.71M) | (208.49M) |
| EBITDA Margin | -800.2% | -653.7% |
| Operating Income | (196.94M) | (235.07M) |
| Operating Margin | -962.6% | -737.0% |
| Interest Income | 18.12M | 13.66M |
| Interest Expense | 2.12M | 1.14M |
| Other Income / Expenses | 15.77M | 12.26M |
| Income Before Tax | (181.17M) | (222.8M) |
| Pre-Tax Margin | -885.5% | -698.6% |
| Income Tax Expense | 212K | 163K |
| Net Income | (173.77M) | (203.15M) |
| Net Margin | -849.4% | -637.0% |
| EPS (Basic) | (1.68) | (4.98) |
| EPS (Diluted) | (1.68) | (4.98) |
| Weighted Avg Shares | 127.45M | 50.09M |
| Weighted Avg Shares (Diluted) | 127.45M | 50.09M |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.